Fintel reports that on April 7, 2026, Citigroup downgraded their outlook for Bio-Rad Laboratories (NYSE:BIO.B) from Buy to Neutral. Analyst Price Forecast Suggests ∞% Upside As of February 25, 2026, ...

Shares of Nuvation Bio (NUVB) climbed ~48% on Wednesday after B. Riley Securities launched its coverage with a Buy recommendation and a $12 per share target, citing early signs of a successful ...

HERCULES, Calif. (AP) — HERCULES, Calif. (AP) — Bio-Rad Laboratories Inc. (BIO.B) on Thursday reported fourth-quarter net income of $720 million, after reporting a loss in the same period a year ...

Fintel reports that on October 30, 2025, Wells Fargo maintained coverage of Bio-Rad Laboratories (NYSE:BIO.B) with a Equal-Weight recommendation. As of April 2, 2025, the average one-year price target ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of four new ...

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the ...

1 Day BIO.B -0.01% DJIA 0.33% S&P 500 -0.13% Health Care/Life Sciences -2.00% ...